Marshall W Pitz1, Elizabeth A Eisenhauer1, Mary V MacNeil1, Brian Thiessen1, Jacob C Easaw1, David R Macdonald1, David D Eisenstat1, Ankineedu S Kakumanu1, Muhammad Salim1, Haji Chalchal1, Jeremy Squire1, Ming Sound Tsao1, Suzanne Kamel-Reid1, Shantanu Banerji1, Dongsheng Tu1, Jean Powers1, Diana F Hausman1, Warren P Mason1. 1. CancerCare Manitoba, Winnipeg, Canada (M.W.P., S.B.); Queen's University, Department of Oncology, Kingston, Canada (E.A.E.); Dalhousie University,Halifax, Canada (M.V.M.); BritishColumbia Cancer Agency, Vancouver, Canada (B.T.); Tom Baker Cancer Centre, Calgary, Canada (J.C.E.); London Regional Cancer Program, London, Canada (D.R.M.); University of Alberta, Edmonton, Canada (D.D.E.); Allan Blair Cancer Center, Regina, Canada (A.S.K., M.S., H.C.); Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada (J.S.); Department of Pathology, University Health Network, University of Toronto, Toronto, Canada (M.S.T., S.K.-R.); NCIC Clinical Trials Group, Queen's University, Kingston, Canada (D.T., J.P.); Oncothyreon, Inc., Seattle, Washington (D.F.H.); Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada (W.P.M.).
Abstract
BACKGROUND: Glioblastoma (GBM) is the most aggressive malignancy of the central nervous system in adults. Increased activity of the phosphatidylinositol-3-OH kinase (PI3K) signal transduction pathway is common. We performed a phase II study using PX-866, an oral PI3K inhibitor, in participants with recurrent GBM. METHODS: Patients with histologically confirmed GBM at first recurrence were given oral PX-866 at a dose of 8 mg daily. An MRI and clinical exam were done every 8 weeks. Tissue was analyzed for potential predictive markers. RESULTS: Thirty-three participants (12 female) were enrolled. Median age was 56 years (range 35-78y). Eastern Cooperative Oncology Group performance status was 0-1 in 29 participants and 2 in the remainder. Median number of cycles was 1 (range 1-8). All participants have discontinued therapy: 27 for disease progression and 6 for toxicity (5 liver enzymes and 1 allergic reaction). Four participants had treatment-related serious adverse events (1 liver enzyme, 1 diarrhea, 2 venous thromboembolism). Other adverse effects included fatigue, diarrhea, nausea, vomiting, and lymphopenia. Twenty-four participants had a response of progression (73%), 1 had partial response (3%, and 8 (24%) had stable disease (median, 6.3 months; range, 3.1-16.8 months). Median 6-month progression-free survival was 17%. None of the associations between stable disease and PTEN, PIK3CA, PIK3R1, or EGFRvIII status were statistically significant. CONCLUSIONS: PX-866 was relatively well tolerated. Overall response rate was low, and the study did not meet its primary endpoint; however, 21% of participants obtained durable stable disease. This study also failed to identify a statistically significant association between clinical outcome and relevant biomarkers in patients with available tissue.
BACKGROUND:Glioblastoma (GBM) is the most aggressive malignancy of the central nervous system in adults. Increased activity of the phosphatidylinositol-3-OH kinase (PI3K) signal transduction pathway is common. We performed a phase II study using PX-866, an oral PI3K inhibitor, in participants with recurrent GBM. METHODS:Patients with histologically confirmed GBM at first recurrence were given oral PX-866 at a dose of 8 mg daily. An MRI and clinical exam were done every 8 weeks. Tissue was analyzed for potential predictive markers. RESULTS: Thirty-three participants (12 female) were enrolled. Median age was 56 years (range 35-78y). Eastern Cooperative Oncology Group performance status was 0-1 in 29 participants and 2 in the remainder. Median number of cycles was 1 (range 1-8). All participants have discontinued therapy: 27 for disease progression and 6 for toxicity (5 liver enzymes and 1 allergic reaction). Four participants had treatment-related serious adverse events (1 liver enzyme, 1 diarrhea, 2 venous thromboembolism). Other adverse effects included fatigue, diarrhea, nausea, vomiting, and lymphopenia. Twenty-four participants had a response of progression (73%), 1 had partial response (3%, and 8 (24%) had stable disease (median, 6.3 months; range, 3.1-16.8 months). Median 6-month progression-free survival was 17%. None of the associations between stable disease and PTEN, PIK3CA, PIK3R1, or EGFRvIII status were statistically significant. CONCLUSIONS:PX-866 was relatively well tolerated. Overall response rate was low, and the study did not meet its primary endpoint; however, 21% of participants obtained durable stable disease. This study also failed to identify a statistically significant association between clinical outcome and relevant biomarkers in patients with available tissue.
Authors: Nathan T Ihle; Ryan Williams; Sherry Chow; Wade Chew; Margareta I Berggren; Gillian Paine-Murrieta; Daniel J Minion; Robert J Halter; Peter Wipf; Robert Abraham; Lynn Kirkpatrick; Garth Powis Journal: Mol Cancer Ther Date: 2004-07 Impact factor: 6.261
Authors: Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701
Authors: Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Jeffrey J Olson; Lakshmi Nayak; D Ryan Ormond; Patrick Y Wen; Steven N Kalkanis; Timothy Charles Ryken Journal: J Neurooncol Date: 2014-04-17 Impact factor: 4.130
Authors: D W Bowles; W W Ma; N Senzer; J R Brahmer; A A Adjei; M Davies; A J Lazar; A Vo; S Peterson; L Walker; D Hausman; C M Rudin; A Jimeno Journal: Br J Cancer Date: 2013-08-13 Impact factor: 7.640
Authors: Cheppail Ramachandran; Gilda M Portalatin; Adriana M Prado; Karl-Werner Quirin; Enrique Escalon; Steven J Melnick Journal: J Evid Based Complementary Altern Med Date: 2016-07-19
Authors: Patrick Y Wen; Mehdi Touat; Brian M Alexander; Ingo K Mellinghoff; Shakti Ramkissoon; Christine S McCluskey; Kristine Pelton; Sam Haidar; Sankha S Basu; Sarah C Gaffey; Loreal E Brown; Juan Emmanuel Martinez-Ledesma; Shaofang Wu; Jungwoo Kim; Wei Wei; Mi-Ae Park; Jason T Huse; John G Kuhn; Mikael L Rinne; Howard Colman; Nathalie Y R Agar; Antonio M Omuro; Lisa M DeAngelis; Mark R Gilbert; John F de Groot; Timothy F Cloughesy; Andrew S Chi; Thomas M Roberts; Jean J Zhao; Eudocia Q Lee; Lakshmi Nayak; James R Heath; Laura L Horky; Tracy T Batchelor; Rameen Beroukhim; Susan M Chang; Azra H Ligon; Ian F Dunn; Dimpy Koul; Geoffrey S Young; Michael D Prados; David A Reardon; W K Alfred Yung; Keith L Ligon Journal: J Clin Oncol Date: 2019-02-04 Impact factor: 44.544
Authors: Charles A Kunos; Evanthia Galanis; Jeffrey Buchsbaum; Qian Shi; Lewis C Strauss; C Norman Coleman; Mansoor M Ahmed Journal: J Neurooncol Date: 2017-05-30 Impact factor: 4.130